Zhongliu Fangzhi Yanjiu (Jul 2022)

Research Progress of Multi-target CAR-T Cell Therapy for Cancer

  • JIANG Yao,
  • WEN Weihong,
  • YANG Fa,
  • NIE Disen,
  • ZHANG Wuhe,
  • QIN Weijun

DOI
https://doi.org/10.3971/j.issn.1000-8578.2022.21.1224
Journal volume & issue
Vol. 49, no. 7
pp. 709 – 714

Abstract

Read online

Chimeric antigen receptor T cell (CAR-T) is a kind of adoptive cell immunotherapy, in which T cells are genetically modified to exert targeted killing effect on tumors. CAR-T cell therapy has shown remarkable antitumor efficacy for the treatment of tumors, especially for hematological malignancies, but is less effective in solid tumors. Single-target CAR-T is prone to off-target effect during application, and there is a risk of relapse or more refractory treatment. The development of double-target or multi-target CAR-T is expected to extend the antigen coverage of target cells, effectively avoids antigen escape and prevents tumor recurrence, and prolongs the survival time of patients. This article reviews the advances of multi-target chimeric antigen receptor T cell, and discusses the prospect of its development.

Keywords